Andersson M - Search Results

1

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

Lycke J, Svennerholm B, Hjelmquist E, Frisén L, Badr G, Andersson M, Vahlne A, Andersen O. Lycke J, et al. Among authors: andersson m. J Neurol. 1996 Mar;243(3):214-24. doi: 10.1007/BF00868517. J Neurol. 1996. PMID: 8936350 Clinical Trial.

2

Depletion of Vbeta5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis.

Olsson T, Edenius C, Ferm M, Samuelson P, Torrång A, Wallström E, Khademi M, Andersson M, Arfors L. Olsson T, et al. Among authors: andersson m. Eur J Neurol. 2002 Mar;9(2):153-64. doi: 10.1046/j.1468-1331.2002.00370.x. Eur J Neurol. 2002. PMID: 11882056 Clinical Trial.

3

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.

Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, Sellebjerg F, Olsson T. Khademi M, et al. Among authors: andersson m. Eur J Neurol. 2009 Apr;16(4):528-36. doi: 10.1111/j.1468-1331.2009.02532.x. Eur J Neurol. 2009. PMID: 19220425

4

Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.

Ytterberg C, Johansson S, Andersson M, Olsson D, Link H, Holmqvist LW, von Koch L. Ytterberg C, et al. Among authors: andersson m. Acta Neurol Scand. 2007 Aug;116(2):96-9. doi: 10.1111/j.1600-0404.2007.00801.x. Acta Neurol Scand. 2007. PMID: 17661794 Clinical Trial.

5

HLA-DR15 is associated with lower age at onset in multiple sclerosis.

Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. Masterman T, et al. Among authors: andersson m. Ann Neurol. 2000 Aug;48(2):211-9. Ann Neurol. 2000. PMID: 10939572

6

Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.

Khademi M, Wallström E, Andersson M, Piehl F, Di Marco R, Olsson T. Khademi M, et al. Among authors: andersson m. J Neuroimmunol. 2000 Mar 1;103(2):202-10. doi: 10.1016/s0165-5728(99)00184-8. J Neuroimmunol. 2000. PMID: 10696916 Clinical Trial.

7

Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study.

Andersen O, Lygner PE, Bergström T, Andersson M, Vahlne A. Andersen O, et al. Among authors: andersson m. J Neurol. 1993 Jul;240(7):417-22. doi: 10.1007/BF00867354. J Neurol. 1993. PMID: 8410082

8

Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker.

Brundin L, Morcos E, Olsson T, Wiklund NP, Andersson M. Brundin L, et al. Among authors: andersson m. Eur J Neurol. 1999 Sep;6(5):585-90. doi: 10.1046/j.1468-1331.1999.650585.x. Eur J Neurol. 1999. PMID: 10457392 Clinical Trial.

9

Central nervous system nitric oxide formation in cerebral systemic lupus erythematosus.

Brundin L, Svenungsson E, Morcos E, Andersson M, Olsson T, Lundberg I, Wiklund NP. Brundin L, et al. Among authors: andersson m. Ann Neurol. 1998 Oct;44(4):704-6. doi: 10.1002/ana.410440421. Ann Neurol. 1998. PMID: 9778274

10

Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters.

Johansson JO, Larson G, Andersson M, Elmgren A, Hynsjö L, Lindahl A, Lundberg PA, Isaksson OG, Lindstedt S, Bengtsson BA. Johansson JO, et al. Among authors: andersson m. Neuroendocrinology. 1995 Jan;61(1):57-66. doi: 10.1159/000126813. Neuroendocrinology. 1995. PMID: 7537355 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results